Jove
Visualize
Contact Us

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adding high-dose celecoxib to increase effectiveness of standard glioblastoma chemoirradiation.

Annales pharmaceutiques francaises·2021
Same author

Short review of SEC, a potential dexamethasone-sparing regimen for glioblastoma: Spironolactone, ecallantide, clotrimazole.

Neuro-Chirurgie·2021
Same author

Dapsone as treatment adjunct in ARDS.

Experimental lung research·2020
Same author

Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro.

Neurochemical research·2017
Same author

Glioblastoma treatment using perphenazine to block the subventricular zone's tumor trophic functions.

Journal of neuro-oncology·2013
Same author

Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells.

Biochimie·2012
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 30, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.6K

Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

R E Kast1

  • 1IIAIGC Study Center, 22 Church Street, Burlington, VT 05401 USA.

Springerplus
|November 7, 2015
PubMed
Summary

The antibiotic dapsone may enhance erlotinib cancer therapy by inhibiting interleukin-8. Dapsone also shows potential to reduce erlotinib-induced skin rash, improving patient quality of life.

Keywords:
DapsoneErlotinibGlioblastomaInterleukin-8NeutrophilsNon-small cell lung cancerOvarian cancerPancreas cancerQuality of lifeRash

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

630

Related Experiment Videos

Last Updated: Mar 30, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.6K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

630

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, shows limited anti-cancer potency due to compensatory increases in interleukin-8.
  • Interleukin-8 (IL-8) promotes tumor growth, metastasis, and angiogenesis, and is natively synthesized by cancer cells.
  • Many chemotherapy drugs, like erlotinib, can increase IL-8 synthesis in malignant cells.

Purpose of the Study:

  • To investigate the potential of dapsone to augment erlotinib's anti-cancer efficacy.
  • To explore dapsone's ability to mitigate erlotinib-induced side effects, specifically skin rash.
  • To evaluate dapsone's impact on the interleukin-8 system in the context of cancer therapy.

Main Methods:

  • Review of existing literature on dapsone's effects on the interleukin-8 system.
  • Analysis of dapsone's known therapeutic roles in neutrophilic dermatoses.
  • Correlation of erlotinib-induced rash with keratinocyte IL-8 synthesis.

Main Results:

  • Dapsone exhibits multiple actions that inhibit the interleukin-8 system.
  • Erlotinib treatment commonly causes a rash resulting from up-regulated keratinocyte IL-8 synthesis.
  • Dapsone is an established treatment for neutrophilic dermatoses, sharing histological similarities with erlotinib rash.

Conclusions:

  • Dapsone has the potential to enhance erlotinib's anti-cancer activity by counteracting IL-8-mediated tumor promotion.
  • Dapsone may improve patient quality of life by ameliorating erlotinib-induced skin rash.
  • Combining dapsone with erlotinib could offer a dual benefit in cancer treatment.